NCT04684771 is a NA clinical trial of MYOSTIM® in Anterior Cruciate Ligament Rupture, sponsored by Alternativa International S.A.

Who is sponsoring NCT04684771?

NCT04684771 is sponsored by Alternativa International S.A.

What drugs are being tested in NCT04684771?

Interventions in NCT04684771: MYOSTIM®, PLACEBO.

What condition does NCT04684771 study?

NCT04684771 studies Anterior Cruciate Ligament Rupture.

Is NCT04684771 still recruiting?

NCT04684771 is currently completed. Last updated 28 December 2020.

Last reviewed 2020-12-28 · How we verify

NCT04684771

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tolerance, Efficacy, revAlidation, Myostim

Completed NA Last updated 28 December 2020

What this trial tests

NA trial testing MYOSTIM® in Anterior Cruciate Ligament Rupture in 35 participants. Completed in 31 December 2017.

Timeline

23 March 2015

Primary endpoint
27 July 2017

31 December 2017

Quick facts

Lead sponsor	Alternativa International S.A
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	supportive care
Enrollment	35
Start date	23 March 2015
Primary completion	27 July 2017
Estimated completion	31 December 2017
Sites	2 locations across Belgium

Drugs / interventions tested

MYOSTIM®
PLACEBO

Conditions studied

Anterior Cruciate Ligament Rupture — all drugs for Anterior Cruciate Ligament Rupture →

Sponsor

Alternativa International S.A

Who can join

Adults 18 to 40, any sex, with Anterior Cruciate Ligament Rupture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of efficacy and tolerance of a food supplement (MYOSTIM®) versus a placebo in postoperative revalidation of patients after reconstructive surgery of anterior cruciate ligament. The food supplement (MYOSTIM®) has been developped and is supplied as food bars and composed of pomegranate, leucine, creatine, proteins and D vitamin. The aim of this exploratory study is to assess the efficacy and tolerance of MYOSTIM® on muscle performance after ACL reconstructive surgery and in postoperative revalidation phase.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Anterior Cruciate Ligament Rupture

Currently open trials in the same condition.

NCT07589582 — Active Noise-Cancelling Headphones Reduce Operative Time and Improve Procedural Consistency in ACL Reconstruction l · NA · active not recruiting
NCT06357091 — ACL Reconstruction With Shark Screw® or Biocomposite-interference Screws · NA · recruiting
NCT07333092 — Investigation of the Effects of Proprioceptive Exercises After Anterior Cruciate Ligament Surgery · NA · recruiting
NCT06955026 — Effect of the Hockey Slideboard Training Combined With Blood Flow Restriction (BFR) in the Rehabilitation Following Ante · NA · recruiting
NCT05174611 — Vitamin D to Improve Quadricep Muscle Strength · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04684771 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alternativa International S.A
Last refreshed: 28 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04684771.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing